Results 121 to 130 of about 264,364 (306)

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Mapping of low-voltage bridges with a high-density multipolar catheter in a child with atrioventricular nodal reentry tachycardia

open access: yesHeartRhythm Case Reports, 2020
Fabrizio Drago, MD   +3 more
doaj   +1 more source

An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paroxetine is a selective serotonin reuptake inhibitor (SSRI), approved for treatment of major depressive disorder and anxiety disorders. Some SSRIs are known to prolong the QT interval; however, clinical evidence to establish a lack of association between paroxetine and corrected QT interval (QTc) prolongation is limited. Therefore, this
Sven C. van Dijkman   +6 more
wiley   +1 more source

Impact of a novel algorithm designed to reduce T-wave oversensing with the subcutaneous defibrillator in a patient with type I Brugada electrocardiogram

open access: yesHeartRhythm Case Reports, 2018
Serge Boveda, MD   +3 more
doaj   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale   +5 more
wiley   +1 more source

Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Levothyroxine (LT4) is the standard treatment for hypothyroidism and the most widely prescribed medication worldwide. Although generally safe, regulatory reports list potential cardiac, neuropsychiatric and musculoskeletal adverse events (AEs). Clarifying their clinical relevance is essential.
Bala Swetha Baskaran   +2 more
wiley   +1 more source

Evidence regarding clinical use of microvolt T-wave alternans [Accuracy of microvolt T-wave alternans testing] [PDF]

open access: yes, 2011
Background: Microvolt T-wave alternans (MTWA) testing in many studies has proven to be a highly accurate predictor of ventricular tachyarrhythmic events (VTEs) in patients with risk factors for sudden cardiac death (SCD) but without a prior history of ...
Cohen, Richard J.   +2 more
core  

Fiber‐type soft bioelectronics for wearable and implantable sensing and therapy

open access: yesBMEMat, EarlyView.
Fiber‐type soft bioelectronics are emerging as versatile platforms for wearable and implantable health monitoring and therapeutic applications. These bioelectronics use organic and inorganic matrices combined with advanced fillers, which feature high conductivity, electrochemical sensitivity, softness, and biocompatibility.
Haneul Kim   +5 more
wiley   +1 more source

ROLE OF AUTOIMMUNE REACTIONS IN DEVELOPMENT OF CARDIAC ARRHYTHMIA AND CONDUCTION DISTURBANCES

open access: yesТерапевтический архив, 2012
Cardiac arrhythmias and conduction disturbances are an important cause of morbidity and mortality in many countries all over the world. Etiology of these disorders remains unclear in many patients.
E S Rodionova   +5 more
doaj  

Home - About - Disclaimer - Privacy